enVVeno Medical expects capital to fund company through 3Q26

The Company ended the quarter with $35.1 million in cash and investments. Based on management’s current expectations, this capital has the potential to fund the Company through the third quarter of 2026, including pre-commercialization activities for the VenoValve, and the commencement of the enVVe pivotal study. Cash burn for the quarter was $3.8 million, consistent with the Company’s projected cash burn rate of approximately $4-5 million per quarter. The Company anticipates that its cash burn rate will increase from current levels once commercialization of the VenoValve begins.